Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

NCT04334759 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT04334759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04334759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Lead sponsor
PrECOG, LLC.
Phase
Phase 3
Overall status
Completed
Start date
February 18, 2021
Completion date
June 30, 2025
Enrollment
214 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma, mesothelioma, pleural mesothelioma